- July 21, 2009
- Taiho Pharmaceutical Co., Ltd.
Taiho Pharmaceutical's Anticancer Agent TS-1 Approved for Market in Singapore
Tokyo, July 13, 2009 — Taiho Pharmaceutical Co., Ltd., announced today that it has received marketing authorization for its oral fluoropyrimidine anticancer agent TS-1, in both 20mg and 25mg capsules, in Singapore. The anticancer agent, developed by Taiho, is already available in Japan, South Korea and China.
TS-1 has been approved in Singapore for postoperative adjuvant chemotherapy for gastric cancer, and is scheduled to be marketed under the product name TS-ONE starting this August by Taiho’s local partner, Pharmaforte Singapore Pte. Ltd.
TS-1 has a wide variety of indications and has helped to extend the lives of numerous patients in Japan since its release in 1999. It is used for the treatment of gastric cancer, colorectal cancer, head and neck cancer, non-small cell lung cancer, inoperable or recurrent breast cancer, pancreas and biliary tract cancers. For gastric cancer, TS-1 has become the standard chemotherapy in Japan.
Pharmaforte has already received numerous inquiries from cancer centers in Singapore, which are requesting the earliest possible release. With the large number of clinical trial facilities located in Singapore, the approval of TS-1 is expected to be a major boon for Asia-based chemotherapy research.
Information in this news release was current as of the original release date.